Exploring distinct modes of inter-spike cross-linking for enhanced neutralization by SARS-CoV-2 antibodies.

Publication date: Dec 04, 2024

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its Omicron subvariants drastically amplifies transmissibility, infectivity, and immune escape, mainly due to their resistance to most neutralizing antibodies. Thus, exploring the mechanisms underlying antibody evasion is crucial. Although the full-length native form of antibody, immunoglobulin G (IgG), offers valuable insights into the neutralization, structural investigations primarily focus on the fragment of antigen-binding (Fab). Here, we employ single-particle cryo-electron microscopy (cryo-EM) to characterize a W328-6H2 antibody, in its native IgG form complexed with severe acute respiratory syndrome (SARS), severe acute respiratory syndrome coronavirus 2 wild-type (WT) and Omicron variant BA. 1 spike protein (S). Three high-resolution structures reveal that the full-length IgG forms a centered head-to-head dimer of trimer when binds fully stoichiometrically with both SARS and WT S, while adopting a distinct offset configuration with Omicron BA. 1 S. Combined with functional assays, our results suggest that, beyond the binding affinity between the RBD epitope and Fab, the higher-order architectures of S trimer and full-length IgG play an additional role in neutralization, enriching our understanding of enhanced neutralization by SARS-CoV-2 antibodies.

Open Access PDF

Concepts Keywords
Antibodies Antibodies, Neutralizing
Coronavirus Antibodies, Neutralizing
Electron Antibodies, Viral
Valuable Antibodies, Viral
W328 COVID-19
Cryoelectron Microscopy
Humans
Immunoglobulin Fab Fragments
Immunoglobulin Fab Fragments
Immunoglobulin G
Immunoglobulin G
Models, Molecular
Neutralization Tests
Protein Binding
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
spike protein, SARS-CoV-2

Semantics

Type Source Name
disease IDO infectivity
disease MESH severe acute respiratory syndrome
disease IDO protein
disease IDO role
disease IDO assay
disease MESH dissociation
drug DRUGBANK Coenzyme M
drug DRUGBANK Pentaerythritol tetranitrate
disease IDO site
disease IDO process
drug DRUGBANK Cysteamine
disease IDO cell
disease IDO host
disease MESH viral infection
disease MESH influenza
disease IDO immunodeficiency
disease MESH aids
disease MESH infection
disease MESH SARS CoV 2 infection
disease IDO production
drug DRUGBANK Glycine
drug DRUGBANK L-Lysine
drug DRUGBANK Trypsin
drug DRUGBANK Immune Globulin Human
drug DRUGBANK BIA
drug DRUGBANK Sodium acetate
drug DRUGBANK Tromethamine
drug DRUGBANK Tretamine
drug DRUGBANK Activated charcoal
drug DRUGBANK Copper
drug DRUGBANK Titanium
drug DRUGBANK Sodium lauryl sulfate
drug DRUGBANK Nonoxynol-9
drug DRUGBANK (S)-Des-Me-Ampa
pathway REACTOME Reproduction
disease MESH Infectious Diseases
disease MESH Cancer
disease MESH Rare Diseases

Original Article

(Visited 2 times, 1 visits today)